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A B S T R A C T
Background: Current therapies for neuropathic pain are generally symptomatic and possess several side effects,
limiting their prolonged usage.
Hypothesis/Purpose: Thus, it is urgent to develop novel and safe candidates for the management of this chronical
condition. For this purpose, we investigated the analgesic effect of a standardized extract from Zingiber officinale
Roscoe rhizomes (ZOE) obtained by CO2 supercritical extraction, in a mice model of peripheral neuropathy. We
also explored the mechanism of action of ZOE and its main constituents using an in vitro model of neuroin-
flammation.
Methods: Peripheral mono-neuropathy was induced in mice, by spared nerve injury (SNI). The analgesic effect of
ZOE after oral administration was assessed by measuring mechanical and thermal allodynia in SNI mice. The
mechanism of action of ZOE and its main constituents were investigated using spinal cords samples and in an in
vitro model of neuroinflammation by ELISA, western blotting and immunofluorescence techniques.
Results: Oral administration of ZOE 200 mg kg−1 ameliorated mechanical and thermal allodynia in SNI mice,
with a rapid and a long-lasting effect. ZOE did not alter locomotor activity. In BV2 cells and spinal cord samples,
ZOE, 6-gingerol and 6-shogaol reduced pERK levels, whereas ZOE and terpene fraction reduced HDAC1 protein
levels, inhibited NF-κB signalling activation and decreased IL-1β, TNF-α and IL-6 release. ZOE and each tested
constituent had a positive effect on inflammation-impaired SH-SY5Y cell viability.
Conclusions: The oral administration of ZOE attenuated SNI-induced neuropathic pain symptoms by reducing
spinal neuroinflammation, suggesting ZOE as a novel and interesting candidate for the management of neuro-
pathic pain.
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Introduction
Neuropathic pain (NP) is a multifactorial condition caused by a le-
sion or disease of the somatosensory system, involving different pa-
thophysiological mechanisms. Patients with NP exhibit common signs
of hypersensitivity to pain, including mechanical allodynia, a painful
sensation caused by innocuous stimuli, and hyperalgesia, an increase of
sensitivity to pain (Jensen and Finnerup, 2014). Current therapies for
the management of NP are generally symptomatic and rarely focused on
the actual causes. Furthermore, these medications are characterized by
several well-known side effects, which limit their prolonged use
(Jensen and Finnerup, 2014). Thus, it is urgent to develop novel and
safe candidates for the management of this chronic condition.
According to the World Health Organization (WHO), an increasing
number of patients support the use of herbal treatments because they
are generally considered safer than conventional medicine (Singh et al.,
2017). Recently, an important biological role has been attributed to
curcumin, a phenolic compound derived from Curcuma longa L. (Zin-
giberaceae) rhizome (turmeric), in the management of pain (Sun et al.,
2018). However, even though different strategies have been studied to
improve the absorption of curcumin (i.e. nanocrystals, emulsions, li-
posomes, nanogels), its low bioavailability limits its application as a
therapeutic agent. Moreover, the lack of information about the safety
profile of the novel curcumin formulation, together with their ex-
pensive costs, raised the need to search for other herbal species with
similar activity, but with a more favourable bioavailability profile
(Zhao et al., 2019).
Zingiber officinale Roscoe (Zingiberaceae), commonly known as
ginger, is an Asian-native species belonging to the same family of tur-
meric and it is widely used as a spice. Ginger is enlisted in many official
pharmacopoeias of different countries, including European
Pharmacopoeia 9th ed. The dried rhizome, the part of the plant with
biological activities, contains a complex mixture of bioactive com-
pounds with the essential oil and oleoresin representing the most
abundant substances of the phytocomplex. The non-volatile compo-
nents, to which the characteristic pungent taste is attributed, include
gingerols, shogaols, paradols and zingerone (Semwal et al., 2015).
Several studies have proved that Z. officinale rhizome possesses a broad
range of pharmacological actions and it can be efficiently used for
treating nausea and vomiting, gastrointestinal problems, hypergly-
cemia, dysmenorrhea, inflammatory disorders and pain
(Forouzanfar and Hosseinzadeh, 2018). In spite of the similarity be-
tween ginger and turmeric chemical composition, ginger and its main
constituents have been shown to possess an optimal pharmacokinetic
profile, thus, overcoming one of the main limitation for the therapeutic
use of turmeric. Indeed, it has been recently observed that ginger ad-
ministered via p.o is neuroprotective in different in vivo models of
neurological disorders (Choi et al., 2018), supporting its capability to
reach the central nervous system (CNS). Importantly, according to the
European Medicines Agency (EMA), safety data for ginger are generally
positive and only few minor adverse effects have been observed
(EMA, 2012). Thus, the aim of our study was to investigate the possible
analgesic effect of a standardized Z. officinale rhizomes extract (ZOE)
obtained by CO2 supercritical extraction, in a mice model of peripheral
mononeuropathy, i.e. the spared nerve injury (SNI), to further elucidate
exploring the mechanism of action of ZOE and its main constituents in
an in vitro model of neuroinflammation.
Materials and methods
Chemicals
ZOE, obtained by supercritical CO2 extraction, and standardized to
contain 24.73% total gingerols and 3.03% total shogaols, was kindly
provided by INDENA S.p.A. (Milan, Italy), batch number 46349. 6-
gingerol (GIN) was purchased from Sigma-Aldrich (Milan, Italy) and 6-
shogaol (SHO) was purchased from Extrasynthese (Genay, France). GC
grade n-Hexane was from J.T. Baker (Milan, Italy). U0126 was pur-
chased from Calbiochem (Milan, Italy). Bacterial lipopolysaccharide
(LPS) from Gram- (Salmonella enteridis) was purchased from Sigma-
Aldrich. All the analytical standards were from Sigma Aldrich.
Quantification of 6-gingerol and 6-shogaol by HPLC-DAD
ZOE was diluted 100-fold in 96% v/v ethanol and filtered through
0.45 µm membrane before HPLC-DAD analysis. A Shimadzu
Prominence LC 2030 3D instrument, equipped with a Bondapak® C18
column (300 × 3.9 mm, 10 µm, 125 Å, Waters Corporation, Milford,
MA, USA) as the stationary phase, was used. The mobile phase was
composed of water with 0.5% formic acid (A) and acetonitrile with
0.1% formic acid (B), under the following gradient: from 50% A to 45%
A in 8 min, followed by an isocratic phase until 10 min. The flow rate
was 0.9 ml/min and the injection volume was 10 µl.
The absorbance was recorded at 280 nm and the quantification of
GIN and SHO was performed according to the calibration curves ob-
tained using analytical grade standards.
Qualitative and semi-quantitative analysis of ZOE volatile compounds
Volatile compounds in ZOE were analysed by means of gas chro-
matography coupled with a flame ionization detector (GC-FID) and
with a mass spectrometer (GC-MS), using an Agilent Technologies
(Waldbronn, Germany) 7820A instrument. For GC-MS, a 5975C net-
work mass spectrometer (Agilent Technologies) was used.
The following conditions were applied for both GC-FID and GC-MS:
compounds were separated on an Agilent Technologies HP-5 cross-
linked poly-5% diphenyl–95% dimethyl polysiloxane (30 m× 0.32 mm
i.d., 0.25 µm film thickness) capillary column. The injection volume
was 0.1 μl with a split ratio of 1:20 and 1:40 in GC-FID and GC-MS
analysis, respectively. The column temperature was initially set at 45
°C, then increased to 100 °C at a rate of 2 °C/min up, then raised to 250
°C at a rate of 5 °C/min, which was held for 5 min. Helium was used as
the carrier gas at a flow rate of 1.0 ml/min. The injector and FID de-
tector temperature were set at 250 and 300 °C, respectively. Concerning
the MS detector, the transfer line and ion-source temperature were 280,
and 230 °C, respectively. MS detection was performed with electron
ionization (EI) at 70 eV, operating in the full-scan acquisition mode in
the m/z range 40–400. The sample was diluted 1:20 (v/v) with n-
hexane before GC-FID and GC-MS analyses. The analyses were per-
formed in triplicate.
Compounds were identified by comparing the retention times of the
chromatographic peaks with those of authentic reference standards run
under the same conditions and by comparing the experimental linear
retention index (LRI) values, calculated from a mixture of n-alkanes
(C8–C40) in n-hexane and injected under the same conditions as those
previously described in the literature (Adams, 2007). Peak enrichment
by co-injection with authentic reference compounds was also carried
out. Comparison of the MS-fragmentation pattern of the target analytes
with those of pure components was performed. A mass-spectrum da-
tabase search was performed by using the National Institute of Stan-
dards and Technology (NIST, Gaithersburg, MD, USA) mass-spectral
database (version 1.4). The percentage relative amount of individual
components was expressed as percent peak area relative to total peak
area.
Terpenoid-enriched fraction extraction and quantification
The extraction of the terpenoid-enriched fraction (ZTE) was per-
formed as previously described (Ferguson, 1956). ZOE (100 mg) was
soaked in 10 ml of 96% v/v ethanol for 24 h. The extract was filtered
and then extracted with 10 ml of petroleum ether, using a separating
funnel. The petroleum ether extract was separated in pre-weighed 15
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ml tubes and evaporated. The yield (%) of ZTE content was calculated
using the following formula:
− ×(wi wf/wi 100)
where wi is the initial weight of ZOE and wf is the final weight of the
petroleum ether extract after evaporation.
Animals
CD1 male mice (20-22 g) from the Envigo (Varese, Italy) were used.
Mice were randomly assigned to standard cages, with four to five ani-
mals per cage. The cages were placed in the experimental room 24 h
before behavioural testing for acclimatization. The animals were fed a
standard laboratory diet and tap water ad libitum and kept at 23 °C with
a 12 h light/dark cycle, light on at 07:00 h. All animal care and ex-
perimental protocols were in compliance with international laws and
policies (Directive 2010/63/EU of the European parliament and of the
council of 22 September 2010 on the protection of animals used for
scientific purposes; Guide for the Care and Use of Laboratory Animals,
US National Research Council, 2011) and were approved by the Animal
Care and Research Ethics Committee of the University of Florence,
Italy, under license from the Italian Department of Health (54/2014-B,
410/2017-PR). Animal studies are reported in compliance with the
animal research: reporting of in vivo experiments (ARRIVE) guidelines
(Kilkenny et al., 2010; McGrath and Lilley, 2015). All efforts was taken
to minimize the number of animals used and their suffering. Mice were
sacrificed by cervical dislocation for removal of spinal cord for in vitro
analysis. The number of animals per experiment was based on a power
analysis (Charan and Kantharia, 2013) and calculated by G power
software. To determine the anti-nociceptive effect, each tested group
comprised 8 animals.
Drug administration
Mice were randomly assigned to each group by an individual other
than the operator. ZOE was dissolved in 1% sodium carboxymethyl
cellulose (CMC) and administered by gavage before testing at the doses
of 100, 200 and 400 mg kg−1 to determine the dose-response curve. For
repeated administration, ZOE (200 mg kg−1) was administered once
daily by gavage for 7 days starting from three days after surgery. The
control group received equivalent volume of the vehicle.
Pregabalin (30 mg kg−1 i.p) (Sigma Aldrich) used as a reference
drug, was dissolved in saline and administered intraperitoneally 3 h
before testing. (± )-baclofen (BACL) (4 mg kg−1 s.c) (Sigma Aldirch)
used as a reference drug was dissolved in saline and administered with
subcutaneous injection 45 min before testing. D-amphetamine hydro-
chloride (AMPH) (2 mg kg−1 i.p) (Sigma Aldrich) used as a reference
drug was dissolved in saline and administered intreaperitoneally 15
min before testing.
LG325, a selective histone deacetylase 1 (HDAC1) inhibitor, was
synthesized in the laboratory of Prof. Maria Novella Romanelli
(University of Florence, Italy) and administered 5 μg per mouse by in-
trathecal (i.t.) injection 15 min before the tests, as previously described
(Sanna et al., 2017). U0126, a well-known mitogen-activated protein
kinase (MEK) inhibitor, (20 μg per mouse) was dissolved in 20% di-
methyl sulfoxide (DMSO) and it was administered i.t. 60 min before
testing.
SNI procedure
Behavioural tests were performed before surgery to establish a
baseline for comparison with postsurgical values. Surgery was per-
formed as described by others (Bourquin et al., 2006). Mice were an-
esthetized with a mixture of 4% isoflurane in O2/N2O (30:70 v/v) and
placed in a prone position. The right hind limb was slightly elevated
and a skin incision was made on the lateral surface of the thigh. The
sciatic nerve was exposed at mid-thigh level distal to the trifurcation
and freed of connective tissue; the three peripheral branches (sural,
common peroneal and tibial nerves) of the sciatic nerve were exposed
without hurting nerve structures. Both tibial and common peroneal
nerves were ligated with a microsurgical forceps (5.0 silk, Ethicon;
Johnson & Johnson Intl, Brussels, Belgium) and transacted together.
The sural nerve was carefully preserved by avoiding any nerve stretch
or contact with surgical tools. Muscle and skin were closed in two
distinct layers with silk 5.0 sutures. Intense, reproducible and long-
lasting thermal and mechanical allodynia-like behaviour are measur-
able in the non-injured sural nerve skin extensions. The sham procedure
consisted of the same surgery without ligation and transection of the
nerves.
Nociceptive behaviour
Animals were habituated to the testing environment daily for at
least 2 days before baseline testing. Nociceptive responses to a me-
chanical or thermal stimulus were measured before and 3, 7 and 10
days after surgery and each mouse possess its own control. All testing
was performed with a blind procedure.
Mechanical threshold (von Frey's test)
Mechanical allodynia was measured by using a Dynamic Plantar
Aesthesiometer (Ugo Basile, Gemonio, Italy) as previously described
(Sanna et al., 2015).
Hargreaves’ plantar test
The thermal nociceptive threshold was measured using Hargreaves’
device (Hargreaves et al., 1988). Paw withdrawal latency in response to
infrared heat was assessed using the plantar test apparatus (Ugo Basile).
Each mouse was placed under a transparent plexiglass box (7.0 × 12.5
cm2, 17.0 cm high) on a 0.6-cm-thick glass plate and allowed to ac-
climatize for 1 h before recording. The radiant heat source consisted of
an infrared bulb (Osram halogen-bellaphot bulb; 8 V, 50 W) that was
positioned 0.5 cm under the glass plate directly beneath the hind paw.
The time elapsed between switching on the infrared radiant heat sti-
mulus and paw withdrawal response was measured automatically. The
intensity of the infrared light beam was chosen to give baseline la-
tencies of 10 s in control mice. A cut-off of 20 s was used to prevent
tissue damage. Each hind paw was tested two-three times, alternating
between paws with an interval of at least 1 min between tests. The
interval between two trials on the same paw was of at least 5 min.
Nociceptive response for thermal sensitivity was expressed as thermal




Possible side effects of ZOE on motor performance were assessed by
rotarod test, as previously described (Sanna et al., 2019).
Hole-board test
The spontaneous locomotor activity was evaluated by using the
hole-board test, as previously described (Sanna et al., 2019).
In vitro neuroinflammation and neuroprotective model
For detailed description of the cell culture conditions and the cell
viability assay please see Supplementary information. In brief, im-
mortalised murine microglial cells (BV2) were seeded in 6-well plates
(3 × 105 cells/well) and pre-treated with ZOE 10 µg/ml or GIN, SHO
and ZTE at the respective concentrations in the extract, for 4 h and then
stimulated with LPS 250 ng/ml for 24 h. Then, the conditioned BV2
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medium was collected and centrifuged (1000 x g for 10 min, 37 °C). The
pellet was discarded and the supernatant was stored at - 80 °C for cy-
tokines dosages or used to treat immortalised human neuroblastoma
(SH-SY5Y) cells (5 × 105 cells/well in 96-well plates). The neuropro-
tective effect of ZOE and its constituents was evaluated by assessing the
cell viability of the SH-SY5Y cells treated with the conditioned BV2
medium for 24 h. Unstimulated BV2 medium was used as control.
LG325 (5 µM) and U0126 (5 µM) were used as HDAC1 and MEK po-
sitive control, respectively.
Preparation of tissue and cell lysates, ELISA, western blot and
immunofluorescence
The detailed protocols used for preparing tissue and cell lysates and
for performing enzyme-linked immunoabsorbant assay (ELISA), wes-
tern blot and immunofluorescence are described in the Supplementary
information.
Statistical analysis
The data and statistical analysis in this study comply with the re-
commendation on experimental design and analysis in pharmacology
(Curtis et al., 2018). The behavioural data are presented as means±
SEM. Eight mice per group were used. Two-way analysis of variance
(ANOVA) followed by Bonferroni post hoc was used for statistical ana-
lysis. For the locomotor activity, the unpaired sample t-test was per-
formed. For in vitro analysis data are expressed as the mean± SEM of
five experiments and assessed by One-way ANOVA followed by Tukey
post hoc test. For each test a value of p < 0.05 was considered sig-
nificant. The computer programme GraphPad Prism version 5.0
(GraphPad Software, San Diego, CA, USA) was used in all statistical
analysis.
Results
Chemical characterization of ZOE
The chemical characterization of ZOE is shown in the Tables 1 and 2
and the HPLC and GC chromatograms are reported in the Supplemen-
tary information (Fig. 1S and 2S). ZOE contains 24.73% total gingerols
and 3.03% total shogaols, and the amount of GIN and SHO resulted to
be 10.07% and 1.68%, respectively.
Regarding the volatile fraction, ZTE was found to be 30.10 %, with
zingiberene being the most abundant volatile constituent (28.2%).
Effect of ZOE on anti-nociceptive activity
SNI induced mechanical (Fig. 1A) and thermal allodynia (Fig. 1D) in
the ipsilateral side, starting from 3 days after surgery up to day 21. No
hypersensitivity was observed in the contralateral side (Fig. 1A, D). The
dose-response study performed seven days after surgery showed that
oral administration of ZOE completely prevented mechanical (Fig. 1B)
and thermal allodynia (Fig. 1E) at the dose of 200 mg kg−1 and no
further increase of activity was observed at higher doses. The dose of
100 mg kg−1 was ineffective. Time-course experiments showed that, 30
min after the administration, ZOE 200 mg kg−1 has a tendency to
reduce nociceptive symptoms, which became statistically significant
after 60 min and peaked at 120 min (Fig. 1B, E). Although it did not
reach significant, ZOE still maintains a tendency to reduce allodynia
three h after administration. Notably, the intensity of the anti-hyper-
algesic effect of ZOE 200 mg kg−1 was similar to that induced by
pregabalin (30 mg kg−1), used as positive control, without any effect on
contralateral side (Fig. 1E, F).
Oral repeated administration of ZOE 200 mg kg−1 reverted me-
chanical allodynia in the ipsilateral side 7 and 10 days post-surgery
(Fig. 1G). The administration of ZOE on SNI exposed to repeated ad-
ministration of the extract showed a time course similar to the acute
administration, with a maximum effect between 60 and 120 min
(Fig. 1H). Repeated exposure to ZOE induced a significant increase of
the basal mechanical threshold compared to untreated SNI mice. ZOE
administration in mice exposed to repeated treatment induced a peak
effect more consistent than acute administration. Repeated adminis-
tration showed a trend (that did not reach significance) towards an
increase in the contralateral side thermal and mechanical threshold
(Fig. 1I).
Effect of ZOE p.o. administration on locomotor activity
Mice treated with the highest effective dose of ZOE (200 mg kg−1)
were evaluated for motor coordination, by means of the rotarod test,
and for spontaneous mobility and exploratory activity, by means of the
hole board test. Overall, ZOE-exposed SNI mice did not show any gross
behaviour alterations. Oral administration of ZOE did not alter motor
Table 1
HPLC-DAD quantification of 6-gingerol (GIN), 6-
shogaol (SHO) and terpenoid-enriched fraction
(ZTE) in the standardized extract from Zingiber of-
ficinale Roscoe rhizomes (ZOE). Data are expressed






Chemical composition of the volatile compounds in the standardized extract
from Zingiber officinale Roscoe rhizomes (ZOE). Data are expressed as % relative
peak area± standard deviation
Peak number Compound LRI % Area
1 Ethyl butanoate 805 1.7± 0.9
2 α-pinene 933 1.5± 0.2
3 Camphene 947 4.1± 0.8
4 β-pinene 976 0.2a
5 β-myrcene 988 0.3a
6 Octanal 992 0.8± 0.1
7 α-phellandrene 1005 0.7± 0.2
8 β-thujene 1029 4.6± 1.1
9 1,8-cineole 1031 2.3± 0.4
10 Terpinolene 1088 0.3a
11 β-linalool 1101 0.9a
12 Endoborneol 1166 1.4± 0.1
13 Terpinen-4-ol 1178 0.3a
14 α-terpineol 1191 0.8± 0.3
15 Verbenone 1208 0.7± 0.5
16 Neral 1246 0.9a
17 Geraniol 1260 0.4± 0.2
18 Geranial 1275 1.5a
19 α-copaene 1380 0.6± 0.2
20 β-elemene 1386 0.6a
21 α-cedrene 1395 0.8± 0.3
22 α-gurjunene 1409 0.6± 0.3
23 α-bergamotene 1439 0.7± 0.2
24 β-farnesene 1461 0.8± 0.1
25 Aromadendrene 1468 0.5± 0.2
26 Germacrene D 1484 0.6± 0.2
27 α-curcumene 1488 6.2± 0.1
28 Zingiberene 1502 28.2± 0.3
29 γ-muurolene 1505 2.3± 0.2
30 (E,E)-α-farnesene 1513 6.9a
31 β-bisabolene 1515 4.3a
32 β-sesquiphellandrene 1531 11.0± 0.2
33 δ-cadinene 1538 0.5a
34 (E)-nerolidol 1560 0.1a
35 Germacrene B 1568 0.4± 0.1
TOTAL 88.6± 0.8
a SD < 0.05
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coordination (Fig. 2A), exploratory activity (Fig. 2B) or spontaneous
mobility (Fig. 2C), compared to the control group.
Effect of ZOE on ERK 1/2 activation in vivo and in vitro
Mitogen-activated protein kinases (MAPKs) play an important role
in the spinal mechanism of NP and neuroinflammation
(Edelmayer et al., 2014). The role of these kinases in the cellular me-
chanism of action of ZOE was, thus, investigated in SNI animals and in
BV2 cells. Consistently with other published work (Subedi et al., 2019),
the peak of extracellular signal-regulated kinase (ERK) and p38 mi-
togen-activated protein kinases (p38) MAPKs phosphorylation in BV2
cells was observed at 30 min of LPS stimulation. The reliability of the in
vitro model was confirmed by using U0126 10 µM, a well-known MEK
inhibitor, as a positive control. ZOE was used at the concentration of 10
µg/ml according to previously performed cell viability assay (Fig. 3S;
Supplementary information) and it was able to reduce ERK1/2 activa-
tion (Fig. 3A; 3B), while no effect was observed on p38 phosphorylation
(Fig. 3C). To confirm that the effect observed in ZOE-treated BV2 cell
concurs with the in vivo mechanism of action, we evaluated its effects
Fig. 1. Anti-nociceptive effects of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) in SNI mice. (A) The long-lasting mechanical allodynia
produced by SNI up to 21 days after surgery. (B) The dose-response and the time course curve showed the effect of ZOE 100, 200 and 400 mg kg−1 against
mechanical allodynia. (C) Comparison of the effect of ZOE (p.o. 200 mg kg−1) on mechanical allodynia to that produced by pregabalin (i.p 30 mg kg−1). (D) The
long-lasting thermal hyperalgesia produced by SNI model in mice. (E) The effect of acute oral administration of ZOE 100, 200 and 400 mg kg−1 on thermal allodynia
after SNI surgery. (F) Comparison of the effect of ZOE 200 mg kg-1 on thermal hyperalgesia to that produced by pregabalin (i.p 30 mg kg−1). (G) The effect of ZOE
200 mg/kg on mechanical allodynia at 3, 7 and 10 days after surgery. (H) Time course of oral repeated administration of ZOE 200 mg kg−1. (I) Comparison of the
effect on mechanical allodynia between acute and repeated administration of ZOE 200 mg kg−1. Data points represent the mean±SEM obtained from experiments
conducted on 8 mice. *** p < 0.001; ** p < 0.01; * p < 0.05 vs. contralateral side; °°° p < 0.001; °° p < 0.01; ° p < 0.05 vs. ipsilateral side before the treatment.
Fig. 2. Lack of effect of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) on locomotor behaviour. Lack of impairment of (A) motor co-
ordination compared to BACL (* p < 0.05 vs. CTRL), (B) exploratory activity and (C) spontaneous mobility compared to AMPH (*** p < 0.001 vs. CTRL) in mice
treated with ZOE 200 mg kg−1. Data were recorded at the peak of antinociceptive activity.
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Fig. 3. Effect of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) on MAPKs phosphorylation in BV2 cells and in the spinal cord of SNI mice.
Effect of ZOE 10 µg/ml on pERK1/2 (A-B) and pp38 (C) protein levels in BV2 cell after 30 min of LPS *** p< 0.001 vs. untreated BV2; °°° p< 0.001; °° p< 0.01; °p<
0.05 vs. LPS-stimulated BV2; §§ p< 0.01 vs. ZOE + LPS; § p < 0.05 vs. ZOE + LPS; Effect of ZOE mg kg−1 acute oral administration on the activation of pERK1/2 (D-
E), pp38 (F) and pJNK1 (G) activation induced by SNI model in spinal cord samples. Effect of repeated oral administration of ZOE 200 mg kg−1 on pERK1/2 (H-I),
pp38 (J) and pJNK1 (K) in spinal cord of injured mice. Representative blots are reported. *** p< 0.001; ** p< 0.01; * p< 0.05 vs. controlateral side; °° p< 0.01; ° p
< 0.05 vs. SNI mice.
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on MAPKs activation in SNI spinal cord mice samples.
An increase of phosphorylated ERK (pERK)1 (Fig. 3D, H) and pERK2
(Fig. 3E, I) was observed in the ipsilateral side of SNI mice. ZOE com-
pletely prevented ERK1 (Fig. 3D) and ERK2 (Fig. 3E) activation after
acute administration, similarly to U0126 used as positive control.
pERK2 levels were also reduced after repeated treatment (Fig. 3I),
whereas no effect on ERK1 phosphorylation was observed (Fig. 3H). An
increase of phosphorylated p-38 (pp38) levels was observed in the
spinal cord of SNI mice. Consistently with the results obtained in BV2
cells, ZOE did not reduce p38 phosphorylation, neither after acute
(Fig. 3F) nor repeated administration (Fig. 3J).
In agreement with the literature (Zhuang et al., 2006), SNI surgery
group showed an isoform-selective activation for c-Jun n-terminal ki-
nase (JNK), with phosphorylated JNK1 (pJNK1) (p46) being altered in
the injured spinal cord. Acute and repeated treatment with ZOE showed
a tendency to reduce pJNK1 activation (Fig. 3G, K), compared to
pERK1.
Effect of ZOE on HDAC1 protein expression in the spinal cord
As shown in Fig. 4A, LPS induced the up-regulation of HDAC1
protein expression in BV2 cells. This effect was completely prevented by
ZOE pre-treatment, with a similar trend of LG325 a selective HDAC1
inhibitor (Sanna et al.,2017).
Consistently with our previous study (Sanna et al., 2017), SNI mice
showed an increased expression of HDAC1 protein in the ipsilateral side
compared to contralateral side. The increase of HDAC1 was sig-
nificantly prevented by acute (Fig. 4B) and repeated (Fig. 4C) ZOE
administration, with the efficacy being comparable to LG325.
Effect of ZOE on NF-κBp65 nuclear translocation in SNI mice and in BV2
cells
Nuclear factor kappa-light-chain enhancer of activated B cells sub-
unit p65 (NF-κBp65) is one of the most important pathways involved in
inflammatory processes (Shih et al., 2015). Thus, here we investigated
its role in ZOE mechanism of action.
Time-course studies showed that LPS stimulation induced a phos-
phorylated-p65 (pp65) nuclear translocation that peaked 1 h after
treatment (Fig. 4S; Supplementary information). To evaluate the effect
of ZOE on pp65 nuclear translocation, immunofluorescence experi-
ments were carried out. We found pp65 subunit primarily present in the
cytoplasm in unstimulated cells (Fig. 5A), whereas, pp65 level in the
nucleus were increased after 1 h of LPS stimulation (Fig. 5B). The
treatment with ZOE 10 µg/ml blocked the nuclear translocation in LPS-
stimulated cells (Fig. 5C). Analysis by fluorescent staining intensity
confirmed these results. In fact, the intensity of nuclear fluorescence of
pp65 in LPS stimulated cells resulted significantly higher than in the
control group and ZOE pre-treatment prevented pp65 nuclear translo-
cation (Fig. 5D). To confirm that ZOE counteracted the activity of NF-
κBp65 we showed that 24 h after LPS stimulation the total levels of
nuclear factor of kappa light polypeptide gene enhancer in B-cells in-
hibitor alpha (IKBα) increased and ZOE treatment completely reverted
this event (Fig. 5E).
In the spinal cord of SNI mice, we observed an increase of pp65
protein levels, which was completely reverted by ZOE acute treatment
(Fig. 5F). A similar trend was observed for repeated administration,
where the expression levels of pp65 were reduced compared to un-
treated mice (Fig. 5G).
LPS stimulation led to a significant release of the pro-inflammatory
cytokines tumor necrosis factor- α (TNF-α) (Fig. 6A), interleukin-6 (IL-
6) (Fig. 6B) and interleukin-1β (IL-1β) (Fig. 6C) in BV2 culture medium,
which was strongly prevented by ZOE pre-treatment. This effect is
confirmed in ipsilateral side of SNI mice, where ZOE significantly re-
duced IL-1β expression levels after both acute (Fig. 5D) and repeated
administration (Fig. 5E).
Effects of ZOE main components in its biological activity
To identify which constituent of ZOE was responsible for its biolo-
gical effects, we tested the activity of GIN, SHO and ZTE, at the con-
centration present in the active dose of ZOE, on pERK activation,
HDAC1 protein levels and NF-κBp65 pathway activation.
Similarly to ZOE, the pre-treatment of BV2 cells with GIN (1 μg
ml−1) and SHO (0.17 μg ml−1) decreased LPS-induced ERK1/2 phos-
phorylation (Fig. 7A, B). In contrast, no effect was observed with ZTE (3
μg ml−1) treatment. To dissect the role of MEK1 and the possible
binding mode of ZOE constituents in its active site, we performed
molecular docking simulations, using U0126 as a positive control. The
docking software was able to accurately predict the binding mode of
U0126, with a root-mean square deviation (RMSD) of 0.103, compared
to the original coordinates in the crystal structure. Gingerols and sho-
gaols were able to bind the active site of MEK1 with binding energies
ranging from -7 kcal/mol to -7.7 kcal/mol, which are very similar to
that obtained with the known inhibitors (Supplementary information),
suggesting a similar affinity for the active site of MEK1. In contrast, the
volatile compounds gave significantly higher binding energies, except
for zingiberene, α-copaene, α-curcumene, β-bisabolene and β-
Fig. 4. Effect of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) on HDAC1 protein expression. Effect of ZOE (10 µg/ml) on the HDAC1
expression in BV2 after 24 h of LPS stimulation (A). *** p < 0.001 vs. untreated BV2; °°° p < 0.001 vs. LPS-stimulated BV2. Acute (B) and repeated (C) oral
administration of ZOE 200 mg kg−1 effect on HDAC1 protein expression in SNI mice. Representative blots are reported. ** p< 0.01; * p< 0.05 vs. contralateral side;
°° p < 0.01; ° p < 0.05 vs. SNI mice.
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sesquiphellandrene. However, the graphical analysis of the binding
poses revealed that these volatile compounds were not able to replicate
the key interactions needed for the inhibitor binding (Fig. 7C, D, E).
Indeed, U0126 makes multiple hydrogen bonds involving the carbonyl
group of ASP208, PHE209, and the amino group of LYS97, VAL211 and
SER212. Similarly, the carbonyl moiety on the side chain of GIN and
SHO is able to make hydrogen bonds with the amino group of VAL211
and SER212. Moreover, the hydroxyl substituent present on the side
chain of GIN makes a hydrogen bond with the carbonyl group of
PHE209. Both GIN and SHO completely occupy the cavity space, which
accommodates U0126. In the contrast, the zingiberene hydrocarbon
structure cannot make hydrogen bonds with the active site residues,
suggesting a lower affinity for the MEK1 binding site.
Regarding HDAC1, ZTE showed an activity similar to ZOE leading to
a strong reduction of protein expression. Conversely, GIN and SHO did
not modulate this target (Fig. 7F).
Consistently, the increase of IKBα levels, observed after 24 h of LPS
stimulation, was completely reverted by ZTE pre-treatment, with GIN
and SHO showing no effect (Fig. 7G).
Inflammatory factors are known to induce neurotoxicity both in vivo
and in vitro. Similarly to ZOE, ZTE pre-treatment significantly reduced
the LPS-induced release of the pro-inflammatory cytokines TNF-α
(Fig. 8A), IL-1β (Fig. 8B) and IL-6 (Fig. 8C) by BV2 cells. In contrast,
GIN and SHO did not show any significant effect.
Effect of ZOE on inflammation-induced neurotoxicity in SH-SY5Y cells
As shown in Fig. 8D, LPS-conditioned BV2 medium reduced SH-
SY5Y cell viability compared to the untreated control, suggesting that
the pro-inflammatory cytokines secreted by LPS-activated microglia
were able to induce neurotoxicity. LPS-conditioned medium obtained
from ZOE-treated BV2 cells completely prevented this cytotoxic effect,
returning to basal level. LPS-conditioned medium obtained from GIN-,
SHO- and ZTE-treated BV2 cells was also able to significantly protect
SH-SY5Y from the neurotoxic effect of BV2 conditioned medium.
Discussion
Currently, the available treatments for chronic NP are effective in
fewer than 50% of patients, with a series of well-known side effects
limiting the patients’ compliance (Jensen and Finnerup, 2014). For this
purpose, we investigated the pain relieving activity of ZOE in a mice
model of peripheral neuropathy.
A single oral administration of ZOE completely reverted both me-
chanical and thermal allodynia in the ipsilateral side of SNI mice.
Indeed, ZOE increased the pain threshold similarly to pregabalin, which
is used as the first line treatment for NP. Despite there is convincing
scientific evidence regarding the analgesic effect of ginger in the
management of chronic inflammatory pain (Forouzanfar and
Hosseinzadeh, 2018), to the best of our knowledge, no data are
Fig. 5. Effect of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) on NF-κB p65 activation. Representative micrograph showing pp65 nuclear
translocation in untreated (A) and LPS-stimulated (B) BV2, and the effect of ZOE (10 μg ml−1) pre-treatment (C). Scale bar = 20 µm. Immunofluorescence
quantification (D). Effect of ZOE (10 μg ml−1) on pp65 protein expression after 24 h of LPS stimulation in BV2 (E). *** p < 0.001 vs. untreated BV2; °°° p< 0.001 vs.
LPS-stimulated BV2. Effect of ZOE 200 mg kg−1 on pp65 nuclear translocation after acute (F) and repeated (G) administration in SNI mice. ** p < 0.01; * p < 0.05
vs. controlateral side ° p < 0.05 vs. SNI mice).
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Fig. 6. Effects of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) on inflammatory cytokines levels. Quantification of TNF-α (A), IL-6 (B) and
IL-1β (C) released by LPS-stimulated BV2. *** p < 0.001 vs. untreated BV2; °°° p < 0.001 vs. LPS-stimulated BV2; §§ p < 0.01 vs. ctrl. IL-1β expression in SNI mice
after both acute (D) and repeated (E) ZOE 200 mg kg−1 oral treatment. Representative blots are reported. *** p < 0.001; ** p < 0.01; * p < 0.05 vs. controlateral
side; °° p < 0.01; ° p < 0.05 vs. SNI mice.
Fig. 7. Effects of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) main constituents on the modulation of pERK1/2, HDAC1 AND IKBα protein
expression. Effect of ZOE (10 µg/ml), GIN (1 µg/ml), SHO (0.17 µg/ml) and ZTE (3 µg/ml) in the modulation of pERK 1 (A) and pERK2 (B) level induced by LPS (30
min) in BV2 cells. Docking poses of GIN (C, pink), SHO (D, magenta) and zingiberene (E, orange), superimposed with U0126 (green). Polar interactions are depicted
as yellow dashed lines for U0126 and as green dashed lines for ZOE constituents. Modulation by ZOE (10 µg/ml), GIN (1 µg/ml), SHO (0.17 µg/ml) and ZTE (3 µg/
ml) of HDAC1 (F) and IKBα (G) protein levels in LPS-stimulated BV2 cells. Representative blots are reported. *** p < 0.001 vs. untreated BV2; °°° p < 0.001; °° p <
0.01; ° p < 0.05 vs. LPS-stimulated BV2.
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currently available regarding NP. This is the first study to support the
analgesic effectiveness of a standardized Z. officinale extract in a model
of peripheral mono-neuropathy, making it a promising candidate for
the management of neuropathies. Indeed, contrary to the majority of
herbal medicines, which often need repeated administration to achieve
the pharmacological efficacy, ZOE reduced pain hypersensitivity after a
single oral administration. This effect was characterized by a rapid
onset of action, and it persisted up to 3 h after oral administration. This
rapid but long-lasting effect may be related to the favourable pharma-
cokinetic profile of ZOE main constituents (Mukkavilli et al., 2017). At
the same time, compared to conventional drugs used in the manage-
ment of NP, ZOE did not induce tolerance in mice after repeated ad-
ministration. Importantly, in contrast to first line therapy for NP [(e.g.,
pregabalin, which induces somnolence, altered motor coordination and
ataxia (Verma et al., 2014)], ZOE did not cause any alteration in lo-
comotor behaviour, confirming the safety profile of ginger. These im-
portant features may contribute to the amelioration of the NP patients
quality of life, enhancing the therapeutic compliance.
Increasing evidence has emerged on the role of neuroinflammation
in the pathogenesis of NP. In particular, traumatic damages to the
peripheral nerve lead to a robust inflammatory response which may be
involved in the initiation and maintenance of pain hypersensitivity.
Indeed, microglia activation in the spinal cord is involved in synaptic
alterations and can lead to nerve injuries and the insurgence of hy-
persensitivity. To better elucidate the mechanism of action of ginger,
we tested ZOE in an in vitro model of neuroinflammation. LPS-stimu-
lated BV2 cells were used as a validated and in vitro model for re-
producing the effect of microglia activation in animals and they have
been used to investigate the role of neuroinflammation in models of
neuropathic pain (Masuda et al., 2014). One of the most important key
effectors in signal transduction cascade associated with NP are MAPKs
(Edelmayer et al., 2014). Following nerve injury in the dorsal horn of
the spinal cord, activation of MAPKs pathways occurs not only in
neurons but also in glial cells showing a dominant role of microglia in
the development and maintenance of NP (Ji et al., 2009). Thus, to in-
vestigate the analgesic mechanism of action of ZOE, we evaluated
whether the ZOE could modulate MAPKs activation. Our findings in-
dicate a prominent involvement of the ERK pathway in the ZOE cellular
action, as demonstrated by the drastic reduction of ERK1 and ERK2
increased phosphorylation in LPS-stimulated BV2 cells. Consistently
with these results, ZOE reduced ERK activation in the ipsilateral side of
the SNI spinal cord, in a similar manner to U0126. Numerous studies
have reported that MEK1/2 inhibitors reduce ERK activation, leading to
an attenuation of the symptoms associated with NP (Popiolek-
Barczyk et al., 2014). For these reasons, ZOE-induced inhibition of
ERK1/2 activation may represent a main point of its analgesic effect. To
further understanding the mechanism of action of ZOE, we also eval-
uated the effect on JNK1 protein levels in spinal cord. It has been shown
that, after nerve injury, JNK1 preferentially localizes in spinal astro-
cytes and its inhibition leads to the reduction of mechanical allodynia
(Zhuang et al., 2006). ZOE reduced pJNK1 protein levels in the ipsi-
lateral side of spinal cord likely contributing to the analgesic effect of
ginger.
Conversely, p38 appears to play a marginal role since no mod-
ification on pp38 levels was produced in BV2 cells. These data were
further corroborated by the lack of ZOE effect on pp38 levels in SNI
spinal cord following both acute and repeated oral administration. The
prominent modulation of ERK signalling cascade represents a clinical
advantage. Indeed, different MAPKs subtypes play different roles in the
development of NP, such as specific inhibition of specific class of
MAPKs produces positive effects at different stages of the clinical course
of the pathology. ERK over-phosphorylation following nerve injury
Fig. 8. Neuroprotective effect of the standardized extract from Zingiber officinale Roscoe rhizomes (ZOE) and its main components. Effect of ZOE (10 µg/ml), GIN (1
µg/ml), SHO (0.17 µg/ml) and ZTE (3 µg/ml) on the release of TNF-α (A), IL-1β (B) and IL-6 (C) by LPS-stimulated BV2 cells. *** p< 0.001; ** p< 0.01; * p < 0.05
vs. unconditioned BV2 medium; °°° p < 0.001; °° p < 0.01 vs. LPS-conditioned BV2 medium. Protective effect of ZOE 10 μg ml−1, GIN (1 μg ml−1), SHO (0,17 μg
ml−1) and ZTE (3 μg ml−1) on the neurotoxic effect induced by LPS-conditioned BV2 medium (D). *** p<0.001 vs. baseline; °°° p<0.001; °° p< 0.01; ° p<0.05 vs.
LPS-conditioned BV2 medium.
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occurs first in neurons, microglia and, at later stages, in astrocytes in
the ipsilateral dorsal horn. Taking into account that the interaction
between glial and neuronal cells is key for the pathogenesis of pain, the
modulation of ERK activation should be effective in the control of pain
hypersensitivity at both early and later stages (Zhuang et al., 2005).
HDACs control the expression of a plethora of genes involved in
pain perception and they are an emerging target for the control of al-
gesia. Recently, we investigated the role of histone deacetylation in a
model of NP showing an increase of HDAC1 protein expression in the
ipsilateral side of the spinal cord in animal models of mononeuropathy.
The reduction of HDAC1 over-expression by the administration of a
specific HDAC1 inhibitor attenuated pain hypersensitivity (Sanna et al.,
2017). Consistently, we showed that ZOE strongly reduces HDAC1 le-
vels both in LPS-exposed BV2 cells and in SNI spinal cord samples.
Class I HDAC inhibitors have been reported to cause a reduction of
neuroinflammation by modulation of pro-inflammatory cytokine ex-
pression in LPS-stimulated BV2 cells (Durham et al., 2017). An im-
portant cellular event involved in the pro-inflammatory response is the
activation of NF-κBp65 and the subsequent transcription of a program
of pro-inflammatory genes (Shih et al., 2015). Several findings indicate
that the inactivation of NF-κBp65 pathways is linked to the repression
of HDAC1 levels (Lee et al., 2017).
In addition, the activation of NF-κBp65 pathway contributes to the
onset of neuropathic symptoms. Indeed, the silencing of this pathway is
a possible target to control NP in several animal models (Yuan et al.,
2014). In the present work, we demonstrated that ZOE reduces the
nuclear translocation of pp65 and reverts the effect on IKBΑα induced
by LPS in BV2 cells. These results have been confirmed in SNI spinal
cord samples, where ginger reduced the total expression level of pp65
after both acute and repeated administration. Furthermore, NF-κBp65
activation in microglia, by promoting transcription of pro-inflammatory
mediators, may increase the production of reactive oxygen species and
pro-inflammatory cytokines release (Shih et al., 2015). Consistently,
ZOE significantly reduced the release of TNF-α, IL-1β and IL-6 in LPS-
stimulated BV2 cells. This effect was also observed in vivo, by the re-
duction of IL-1β protein levels in the ipsilateral side of the spinal cord of
SNI mice. These data suggest that ZOE may attenuate neuroinflamma-
tion in NP conditions through the modulation of HDAC1 expression. To
investigate the role of ZOE main constituents in its analgesic effect, we
tested the effects produced by GIN, SHO and ZTE. We observed that GIN
and SHO reduced ERK 1/2 phosphorylation, whereas ZTE was com-
pletely ineffective. Molecular docking simulations revealed a better
binding mode for GIN and SHO in the active site of MEK1, compared to
ZTE constituents, confirming the observed experimental activity. Gin-
gerols and shogaols have been widely studied for their anti-in-
flammatory properties, particularly regarding the reduction of NF-
κBp65 activation and pro-inflammatory cytokines release from glial
cells. Surprisingly, no effects on HDAC1, IKBΑα and cytokines release
were observed following GIN and SHO treatment. This discrepancy
might be explained by taking into account that the effects on pro-in-
flammatory mediators are usually observed at concentrations 10-20
fold higher than those used in the present study (Lee et al., 2017). These
lower doses may be insufficient to produce significant effects on the
inflammatory pathways. ZTE showed opposite effects to GIN and SHO
also towards the release of pro-inflammatory mediators. This volatile
fraction largely decreased HDAC1 expression, NF-κB activation and pro-
inflammatory cytokines release. Coherently with recent studies on
zerumbone, a sesquiterpenoid isolated from Zingiber zerumbet (L.)
Roscoe rhizome essential oil (Chung et al., 2008) our results further
support the efficacy of ginger sesquiterpenoids on HDAC1 modulation.
It is well known that the neuroinflammation plays a key role in the
pathogenesis of NP. Currently, the communication between glial cells
and neurons is an essential point for the development of novel thera-
pies. After peripheral nerve injury, the microglia phenotype markedly
changes to a pro-inflammatory phenotype which releases factors al-
tering the normal neuronal activity. This condition seems to be involved
in the initiation and maintenance of persistent NP (Tozaki-Saitoh and
Tsuda, 2019). By treating SH-SY5Y neuronal cells with LPS-conditioned
medium from ZOE-treated BV2 cells, we demonstrated that the anti-
inflammatory effect of ZOE may prevent the induction of neurotoxicity
caused by microglia hyper-activation. Similar results were obtained
with its main constituents, that all produced a partial beneficial effect in
comparison with the complete protection produced by the phytocom-
plex. Thus, our results highlight ZOE as an interesting multi-target
analgesic drug candidate for the management of NP.
Conclusions
In conclusion, we demonstrated that the acute and repeated oral
administration of ZOE (200 mg kg−1) reduced SNI-induced NP symp-
toms. These effects were linked to the reduction of pERK and HDAC1
expression, leading to the inhibition of NF-κB activation and cytokines
release. Oral administration of ZOE might represent an innovative and
interesting perspective in the management of NP-related conditions.
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